Hormone replacement therapy and acquired resistance to activated protein C: Results of a randomized, double-blind, placebo-controlled trial

British Journal of Haematology

Volumn 115, Issue 2, 2001, Pages 415-420

  Høibraaten, Else ^a   Mowinckel, Marie Christine ^a   De Ronde, Hans ^b   Bertina, Rogier M ^b   Sandset, Per Morten ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Activated protein C resistance; Clinical trial; Endogenous thrombin potential; Hormone replacement therapy; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEIN S; THROMBIN;

ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; FEMALE; HETEROZYGOSITY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM;

EID: 0035726564     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03111.x     Document Type: Article

References (28)

1. Mutation in blood coagulation factor V associated with resistance to activated protein C
2. Statistical methods for assessing agreement between two methods of clinical measurement
3. Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight
4. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
5. Risk of venous thromboembolism in users of hormone replacement therapy
6. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C
7. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
8. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: Prospective cohort study and review of literature
9. Prospective study of exogenous hormones and risk of pulmonary embolism in women
10. Hormone replacement therapy with estradiol and risk of venous thromboembolism - A population-based case-control study
11. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - Results of the randomized, double-blind, placebo-controlled Estrogen in Venous Thromboembolism trial (EVTET)
12. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - Results from a randomized and double-blind, placebo-controlled trial
13. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
14. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
15. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women
16. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
17. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy
18. Hormone replacement therapy and haemostatic function
19. A prothrombinase-based assay for detection of resistance to activated protein C
20. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
21. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
22. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C
23. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
24. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study
25. Detection of decreased response to activated protein C during pregnancy by an endogenous thrombin potential-based assay
26. A randomized cross-over study on the effects of levonorges
27. Third-generation oral contraceptive and deep venous thrombosis: From epidemiologic controversy to new insight in coagulation
28. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe